Langerhans cell sarcoma is a rare, high-grade neoplasm with overtly malignant cytological features and the Langerhans phenotype. Herein, we present a rare case of Langerhans cell sarcoma in a 65-year-old female that presented with a painless enlarging mass in her right axillary region, along with the histopathological features and diagnostic characteristics in the light of literature on Langerhans cell sarcoma.
Introduction
Langerhans cell sarcoma (LCS), also known as malignant histiocytosis X, is a rare entity defi ned as a tumor characterized by its LC immunophenotype and appearance. It has a high mitotic rate and anaplastic cytological features, and is usually observed in lymph nodes and skin, but may also affect the liver, spleen, and lungs [1, 2, 3, 4, 5] . The immunoprofi le is (CD1a+, S100+), and some cells should have the characteristic LC features of grooved nuclei and/or Birbeck granules. LCS tends to affect the elderly and has an aggressive clinical course associated with a high mortality rate despite aggressive treatment [4] .
Herein we report a new and unusual case of LCS in a 65-year-old female that presented with a mass in her axillary lymph node. The aim of this report was to emphasize that LCS, although rare, should be considered in the differential diagnosis because of its ability to mimic metastatic lesions in lymph nodes.
Case Presentation
A 66-year-old female presented with a mass in the axilla that had been present for 4-5 months. Neither systemic symptoms nor a positive family history was observed.
The patient had a history of type-2 diabetes mellitus and hypertension, and was using oral antidiabetics and amlodipine. All laboratory tests (complete blood count, serology, and microbiology), ultrasonographic examination, and computed tomography of the head and neck region, lungs, and lower abdomen were normal. At another clinic the mass was excised and diagnosed as breast carcinoma. The patient was referred to our hospital for further investigation and treatment. Paraffi n blocks were sent to our department for further pathological examination.
Microscopic observation showed that the lymph node architecture was partially preserved, with retention of normal or hypoplastic germinal centers (Figure 1 ). The infi ltrate was seen primarily in the parafollicular and subcapsular regions ( Figure 2 ). The patient's sinuses were distended by large and pleomorphic tumor cells that contained abundant pale eosinophilic cytoplasm and bizarre, grooved nuclei ( Figure 3) . Many of the cells exhibited multinucleation, nuclear lobulation, and high mitotic activity (Figure 4 ). The neoplastic cells had the LC immunophenotype, and strongly expressed CD1a and S-100 ( Figure 5, 6 ). The cells were also positive for fascin and weakly positive for CD45. The tumor cells were negative for CD30, ALK-1, CD-2, CD-3, CD-4, CD-8, CD-7, CD-11c, CD-20, CD-21, CD-45 RO, CD-68, granzyme B, Bcl-2 protein, HMB-45, Melan A, EMA, pan cytokeratin, and follicular dendritic cell marker (CD21). The biopsy specimen was diagnosed as LCS. The patient underwent total surgical resection. No chemotherapy or radiotherapy was planned. At the 1-year follow-up the patient was doing well. 
Discussion
Mature/fully-differentiated histiocytic/dendritic cell neoplasms rarely affect hematopoietic or lymphoid tissues. They have been categorized into subtypes based on their location, enzyme histochemistry, ultrastructure, and immunohistochemical features, and are further classifi ed into 5 groups designated by the WHO, as follows: LC histiocytosis (LCH); LCS; interdigitating dendritic cell sarcoma/tumor (IDCS/T); follicular dendritic cell sarcoma/ tumor (FDCS/T); dendritic cell sarcoma, not otherwise specifi ed [6] .
The diagnosis of LCS is based on the following: malignant cytological features, such as atypia, hyperchromatic LCS must be differentiated from histiocytic sarcoma and other dendritic cell tumors. Immunohistochemical studies are essential for the differential diagnosis, and neoplastic cells LCS is usually associated with multiple organ involvement, including the skin, lymph nodes, lungs, bone, spleen, and liver. Patients range in age between 10 and 81 years, with a male-female ratio of approximately 1:1. At present, there are no reports on the organized series of treatment for LCS. The majority of reported cases had a short survival time and a poor prognosis, as shown in Table  1 ; 50% (12 patients) of 24 patients died of the disease within 2 years. Successful treatment of advanced multiple organ diseases is achievable with such systemic combination chemotherapy as the CHOP regimen (cyclophosphamidedoxorubicin hydrochloride-vincristine-prednisolone), which was used in 15 of the published cases [16] . When considering the fi ndings associated with localized LCS, radiotherapy might be the best treatment; however, many more LCS case fi ndings are necessary to more clearly identify an optimal treatment strategy. The presented case was treated with total excision of the mass only, and did not receive adjuvant chemotherapy or radiation. The patient was doing well at the 1-year follow-up.
In conclusion, LCS of the axillary lymph node is a rare lesion that mimics metastasis of breast cancer, both clinically and radiologically. Correct diagnosis can only be made based on histopathological examination. Due to the vastly different treatment options, pathologists should be aware of this unusual neoplasm in order to facilitate correct diagnosis.
